ArticleMedComm2024

Liposome-based in situ antigen-modification strategy for "universal" T-cell-receptor engineered T cell in cancer immunotherapy.

Qin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.